Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Renal Cell Carcinoma Renal Cell Carcinoma for November/December 2020 Study shows no link between race and mortality in clear cell RCC, Four factors may predict better survival with cabozantinib in mRCC, Fear of recurrence highly prevalent in RCC survivors, Risk factors for severe immune-related AEs identified, Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC, More must reads Renal Cell Carcinoma for September/October 2020 ‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients, Durable efficacy with MK-6482 in VHL-associated RCC, Predicting complications of cytoreductive nephrectomy in metastatic RCC, Survey quantifies COVID-19’s impact on oncology, More must readsRenal Cell Carcinoma for July/August 2020 VTE, sepsis risk increased among COVID-19 patients with cancer, Study links gut microbiome and mRCC treatment outcomes, Aspirin may accelerate cancer progression in older adults, Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19, Robotic renal surgery bests open partial nephrectomy, More must readsRenal Cell Carcinoma for May/June 2020 Personalized cancer vaccine may enhance checkpoint inhibitor activity, Video coaching may relieve anxiety and distress for long-distance cancer caregivers, More must readsRenal Cell Carcinoma for March/April 2020 Cancer prevalence among COVID-19 patients may be higher than previously reported, Lymphopenia linked to worse response in RCC, bladder cancer patients on checkpoint inhibitors, Bevacizumab/pembrolizumab deemed safe and active in mRCC, More must readsPages1 2 3 4 last »
